Fida Biosystems

What Fida Biosystems does

Fida Biosystems ApS is a Copenhagen-based life-science tools company that develops and commercialises FIDA (Flow Induced Dispersion Analysis), a first-principles, in-solution biophysical characterisation technology grounded in Taylor Dispersion Analysis and the Stokes-Einstein equation. The flagship Fida Neo instrument delivers more than ten biophysical readouts — including hydrodynamic radius, binding affinity (mM to pM), binding kinetics, aggregation, viscosity, stickiness, polydispersity index, and labelling quality — from a single assay in roughly one day, using as little as 40 nL of indicator and 4 µL of analyte. The platform covers a size range of 0.5 nm to 500 nm and is compatible with crude matrices (serum, plasma, fermentation media, cell lysate) without buffer, pH, or salt restrictions, differentiating it from surface-based techniques such as SPR.

The company sells its instruments, consumables (capillaries, coating solutions, 96-well plates via shop.fidabio.com), and FIDA Software Suite directly to pharmaceutical companies (Bayer, Novartis, GSK, Lilly, Sanofi, AstraZeneca, Novo Nordisk, Bristol-Myers Squibb, Merck, Eisai), biotechnology firms (Moderna, Genmab, Beam Therapeutics, Monte Rosa Therapeutics, Arbor Biotechnologies, C4 Therapeutics, Codiak Biosciences), CROs (Eurofins, Peak Proteins/Sygnature Discovery), and academic institutions (Rockefeller, University of Copenhagen, DTU, Karolinska, Francis Crick Institute). GTM is enterprise field sales with regional business developers, field application scientists, a "Pilot Your Samples" evaluation program, and discovery calls; post-sale enablement is delivered through bi-monthly training in Copenhagen, periodic training in Cambridge, MA, and a Motimate e-learning platform. In December 2025 the company closed a €5 million Series A led by Fåhraeus Startup and Growth with EIFO participation and announced a strategic partnership with Cytiva (a Danaher company) to broaden distribution and co-develop analytical capabilities.

Name

Fida Biosystems

Legal name

Fida Biosystems ApS

Website

https://fidabio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Fida Biosystems is a Copenhagen-based life-science tools company that commercialises FIDA (Flow Induced Dispersion Analysis) technology — an in-solution biophysical characterisation platform — via the Fida Neo instrument, consumables, and software, serving pharmaceutical, biotech, CRO, and academic research customers including Novartis, Bayer, Moderna, and Genmab.

Ownership category

akta.pro rank

Product category

Biophysical Characterization Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Laboratory Quality & GLP/GCLP Compliance (HLAGAKAK)

Keywords

• Biophysical characterization instruments
• Protein interaction analysis
• Nanoparticle measurement
• Flow induced dispersion
• Molecular binding kinetics

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. FIDA Instruments: Sale of Fida Neo and Fida 1 instruments for biophysical analysis. The instruments enable molecular and nanoparticle characterization for drug discovery and research applications.
2. Consumables: Capillaries, 96-well plates, coating solutions, and other consumables sold through the shop.fidabio.com webshop. Includes uncoated, dynamically coated, and permanently coated capillaries.
3. Software License and Support: FIDA Software Suite included with instrument purchase. Optional 21 CFR Part 11 compliant version available. Service agreements with preventive maintenance offered.
4. Training and Services: Advanced user training organized bi-monthly in Copenhagen, Denmark and periodically in Cambridge, Boston, USA. Field application scientist support and regional business developer assistance.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Fida Biosystems manufactures and sells the Fida Neo instrument—an automated, in-solution biophysical characterization system—and the underlying FIDA (Flow Induced Dispersion Analysis) technology, which delivers over 10 readouts including molecular size, binding affinity, binding kinetics, aggregation, viscosity, stickiness, polydispersity, sample loss, and labelling quality from a single assay. The FIDA Software Suite accompanies the instrument, and recurring revenue comes from consumables (capillaries, plates, coating solutions), optional 21 CFR Part 11 compliant software, and advanced user training and service agreements.

Product overview

Fida Biosystems offers a unified product portfolio centered on FIDA (Flow Induced Dispersion Analysis) technology for biophysical characterization. The core offering consists of the Fida Neo instrument—a multiparameter in-solution analysis system—and the underlying FIDA Technology platform that delivers over 10 biophysical readouts including binding affinity, kinetics, molecular size, viscosity, aggregation, and polydispersity. The FIDA Software Suite provides assay design, instrument control, data analysis, and reporting capabilities. The company also operates a Consumables Webshop for purchasing capillaries and accessories. FIDA is used for applications including drug discovery, protein characterization, lipid nanoparticles, CRISPR, and bioprocessing research.

Differentiator

Problem solved

Functional benefit

Products and services

• Fida Neo Instrument A robust, automated instrument for fast, multiparameter in-solution biophysical analysis of molecules and nanoparticles, designed for pharmaceutical, biotech, academic, and CRO users performing protein characterization, binding studies, and quality control.

Quantifiable outcome

• 100+ instruments sold globally
• +6 more outcomes

Named customers27 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

One partnership is on record.

• CytivacoreStrategic or Co-development Partner · 9 December 2025Danaher company and life sciences industry leader collaborating with Fida Biosystems to expand analytical capabilities for protein research. The partnership aims to improve molecular insight for faster drug discovery.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cytiva (Biacore): Cytiva (Danaher) operates the Biacore SPR platform, the dominant surface-based biophysical characterization technology for protein-protein interaction, kinetics, and affinity — directly comparable to FIDA for the same pharma/biotech workflows. Cytiva is also Fida's strategic distribution partner, making it both competitor and channel.
• Malvern Panalytical: Malvern Panalytical (Spectris) offers Zetasizer, MicroCal (ITC/DSC), and other analytical instruments for particle size, zeta potential, and biomolecular stability — a broad biophysical characterization portfolio with overlapping pharma/biotech use cases to FIDA.
• Sartorius: Sartorius is a major bioprocessing and analytics vendor whose Incucyte, Octet (BLI), and biomolecular characterization tools address overlapping pharma/biopharma analytical workflows — especially in bioprocess QC and developability, where FIDA is also positioning via 21 CFR Part 11 software.
• Agilent Technologies: Agilent's Cell Analysis and Biopharma segments include Biacore (now Cytiva), Seahorse, and other analytical platforms used for protein interaction and biophysical characterization. Agilent is also a Fida customer logo, reflecting a partner-channel relationship alongside competitive overlap.
• Molecular Devices: Molecular Devices (Danaher) supplies high-content screening and analytical plate readers used in pharma drug discovery and biophysical assay workflows — a broader incumbent with partial overlap in protein and cell-based analytics used by FIDA's biopharma customers.

Direct peers

• Wyatt Technology: Wyatt Technology (acquired by Waters) provides multi-angle light scattering (MALS), dynamic light scattering, and field-flow fractionation instruments for absolute molecular weight, size, and aggregation analysis — overlapping strongly with FIDA's biophysical characterization readouts for proteins and nanoparticles.
• Nanotemper Technologies: Nanotemper provides Prometheus (nanoDSF), Monolith (MST), and Tycho instruments for protein stability, binding affinity, and thermal shift assays — a direct peer in label-free biophysical characterization of biologics, used in the same pharma/biopharma QC and developability workflows as FIDA.
• Unchained Labs: Unchained Labs sells biologics stability, formulation, and developability tools (e.g., Uncle, Stunner, Hunky) targeting protein formulation, AAV capsid stability, and LNP characterization — directly comparable to FIDA's biologics and gene therapy QC use cases.

Emerging players

• Refeyn: Refeyn commercializes mass photometry — an emerging single-molecule technique for mass measurement of biomolecules and native complexes — competing with FIDA's molecular size and aggregation readouts in protein and AAV analytics workflows.

Others

• Proteros: Proteros is a CRO providing protein crystallography and biophysical services (including Fida instruments as tools in their workflow) — comparable as a downstream service provider using biophysical characterization platforms for pharma drug discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@fidabiosystems
• LinkedInlinkedin.com/company/fida-tech

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fida Biosystems